ATEA PHARMACEUTICALS INC (AVIR) Stock Earnings & Estimates
NASDAQ:AVIR - US04683R1068 - Common Stock
3.47 USD
-0.13 (-3.61%)
3.54 USD
+0.07 (+2.02%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 48.6M | 351.4M 623.05% | -100.00% | 31.053M | ||||||
| EBITDA YoY % growth | -14.6M -53.68% | 12M 182.19% | 231.9M 1,832.50% | -117.249M -147.82% | -141.259M -7.83% | -169.417M -10.03% | -139.922M -6.34% | -158.96M -13.61% | -92.498M 41.81% | |
| EBIT YoY % growth | -14.6M -53.68% | 12M 182.19% | 231.9M 1,832.50% | -124.805M -147.95% | -168.393M -7.91% | -197.841M -10.00% | -260.1M -97.05% | -175.44M 32.55% | -178.5M -1.74% | |
| Operating Margin | N/A | 24.69% | 65.99% | N/A | N/A | N/A | N/A | N/A | -574.82% | |
| EPS YoY % growth | N/A | N/A | 1.36 -4.99% | -1.46 -202.94% | -1.69 -17.14% | -2.00 -21.95% | -1.75 12.28% | -1.74 0.58% | -1.72 1.17% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.45 -21.30% | -0.44 -9.65% | -0.44 -9.65% | -0.43 2.64% | -0.44 2.27% | -0.43 2.33% | -0.43 2.33% | -0.43 | -0.43 2.33% | -0.43 |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||||
| EBITDA Q2Q % growth | -43.86M -43.08% | -46.92M -34.63% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -41.82M -35.05% | -41.82M -18.58% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.44 8.33% | -0.46 | 0.02 | 4.14% |
| Q1 2025 Q2Q % growth | -0.40 46.67% | -0.42 | 0.02 | 4.35% |
| Q4 2024 Q2Q % growth | -0.40 14.89% | -0.38 | -0.02 | -5.99% |
| Q3 2024 Q2Q % growth | -0.37 7.50% | -0.50 | 0.13 | 26.72% |
| Q2 2024 Q2Q % growth | -0.48 -41.18% | -0.78 | 0.30 | 38.49% |
| Q1 2024 Q2Q % growth | -0.75 -74.42% | -0.62 | -0.13 | -21.20% |
| Q4 2023 Q2Q % growth | -0.47 -14.63% | -0.51 | 0.04 | 7.23% |
| Q3 2023 Q2Q % growth | -0.40 -300.00% | -0.49 | 0.09 | 17.73% |
| Q2 2023 Q2Q % growth | -0.34 10.53% | -0.48 | 0.14 | 29.08% |
| Q1 2023 Q2Q % growth | -0.43 15.69% | -0.49 | 0.06 | 11.71% |
| Q4 2022 Q2Q % growth | -0.41 -130.60% | -0.46 | 0.05 | 10.68% |
| Q3 2022 Q2Q % growth | -0.10 70.59% | -0.45 | 0.35 | 77.89% |
| Q2 2022 Q2Q % growth | -0.38 -2,000.00% | -0.53 | 0.15 | 28.81% |
| Q1 2022 Q2Q % growth | -0.51 -250.00% | -0.59 | 0.08 | 14.16% |
| Q4 2021 Q2Q % growth | 1.34 39.58% | 0.17 | 1.17 | 688.22% |
| Q3 2021 Q2Q % growth | -0.34 80.46% | -0.05 | -0.29 | -534.92% |
| Q2 2021 Q2Q % growth | 0.02 | 0.01 | 0.01 | 292.16% |
| Q1 2021 Q2Q % growth | 0.34 | -0.06 | 0.40 | 706.06% |
| Q4 2020 Q2Q % growth | 0.96 | 0.17 | 0.79 | 476.24% |
| Q3 2020 Q2Q % growth | -1.74 | -1.08 | -0.66 | -61.70% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | -100.00% | % | ||
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2022 Q2Q % growth | -100.00% | 3.4M | -3.4M | -100.00% |
| Q4 2021 Q2Q % growth | 192.2M 295.47% | 87.441M | 104.759M | 119.81% |
| Q3 2021 Q2Q % growth | 32.8M | 54.533M | -21.733M | -39.85% |
| Q2 2021 Q2Q % growth | 60.4M | 59.152M | 1.248M | 2.11% |
| Q1 2021 Q2Q % growth | 66M | 32.244M | 33.756M | 104.69% |
| Q4 2020 Q2Q % growth | 48.6M | 45.9M | 2.7M | 5.88% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 70.67% | -12.82% | 39.01% | 24.73% |
| Revenue | N/A | N/A | N/A | N/A |